Helsinn and Biovitrum enter a license agreement for nordic marketing of ALOXI®, a drug that prevents nausea and vomiting in cancer patients
Lugano, Switzerland and Stockholm, Sweden (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and BIOVITRUM AB, a Swedish Biotechnology company, announce the signing of an agreement granting BIOVITRUM the exclusive License and Distribution rights of Aloxi® (Palonosetron hydrochloride) in the NORDIC ...